` OPGN (OpGen Inc) vs S&P 500 Comparison - Alpha Spread

OPGN
vs
S&P 500

Over the past 12 months, OPGN has outperformed S&P 500, delivering a return of 27% compared to the S&P 500's 12% growth.

Stocks Performance
OPGN vs S&P 500

Loading

Performance Gap
OPGN vs S&P 500

Loading
OPGN
S&P 500
Difference

Performance By Year
OPGN vs S&P 500

Loading
OPGN
S&P 500
Add Stock

Competitors Performance
OpGen Inc vs Peers

S&P 500
OPGN
ABBV
AMGN
GILD
VRTX
Add Stock

OpGen Inc
Glance View

Market Cap
49.3m USD
Industry
Biotechnology

OpGen, Inc. is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. The company is headquartered in Rockville, Maryland and currently employs 99 full-time employees. The company went IPO on 2015-05-05. The Company, through its subsidiaries, is focused on developing and commercializing molecular microbiology solutions helping to guide clinicians with actionable information infections caused by multidrug-resistant microorganisms (MDROs). The Company’s product portfolio includes the Curetis Unyvero System and multiplex syndromic panels, Acuitas AMR Gene Panel and Acuitas Lighthouse, and the ARES Technology Platform including ARESdb using next generation sequencing (NGS) technology and Artificial intelligence (AI) powered bioinformatics solutions for antibiotic response prediction, as well as the Curetis CE vitro diagnostic (IVD) marked polymerase chain reaction (PCR) based severe acute respiratory syndrome (SARS) CoV-2 test kit. The Company’s subsidiaries include Curetis GmbH and Ares Genetics GmbH.

OPGN Intrinsic Value
0.33 USD
Overvaluation 93%
Intrinsic Value
Price
Back to Top